Objective:To determine the impact of the introduction of clarithromycin and azithromycin on the treatment and survival of patients with AIDS and disseminatedMycobacterium aviumcomplex (DMAC).Design:Retrospective review over a 3.5‐year interval.Setting:Tertiary‐care, university teaching hospital.Patients:Charts of all patients with cultures of blood or bone‐marrow positive for acid‐fast bacilli (n = 103) were reviewed. Data on laboratory results at the time of DMAC diagnosis, antimycobacterial therapy, antiretroviral therapy, and survival was collected.Results:Prior to the availability of clarithromycin and azithromycin 61.5% of patients received antimycobacterial treatment compared with 92% afterwards (P= 0.0014). Median survival of treated patients was 255 versus 145 days for untreated patients (P< 0.001). Median survival of macrolide‐treated patients was 284 versus 168 days for patients receiving treatment without a macrolide (P= 0.09). Univariate predictors of survival were antimycobacterial treatment, use of antiretrovirals, and year of diagnosis. In a multivariate model, no antimycobacterial treatment (hazard ratio, 3.83;P= 0.003) was associated with shorter survival, and treatment without a macrolide (hazard ratio, 2.29;P= 0.075) showed a trend towards shorter survival versus treatment with macrolide‐containing regimens.Conclusions:The introduction of clarithromycin and azithromycin has been associated with an increase in the proportion of patients with DMAC receiving treatment and with increased survival of these patients.